4Sawada M,Tsurumi H,Yamada T,et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy[J]. Eur J Haematol,2002,68(6):
5Shipp MA, Mauch PM, Harris NL. Non-Hodgkin's lymphomas[A]. In: Devita VT Jr, Hellmen S, Rosenberg SA, eds. Cancer, principles and practice of oncology[M].5ed. Philadelphia:New York :Lippincott-Raven. 1997:2165-2220.
6Tirelli U, Errante D, Van GM, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of
7Ezzat AA, Ibrahim EM, Stuart RK, et al. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial[J]. Med Oncol,2000,17(1): 39-46.
8Brade WP, Herdrich K, Varini M, et al. Ifosfamide-pharmacology, safety and theraputic potential[J]. Cancer Treat Rev,1985,12(1):1-47.
9Pohlman B. Ifosfamide in the treatment of non-Hodgkin's lymphoma[J]. Semin Oncol, 1996,23(3 Suppl 6): 27-32.
10Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma[J]. N Engl J Med,1993,328(14):1002-1006.
